NAMSA , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc . (Nasdaq: NSPR), developer of the CGuardâ„¢ Embolic Prevention...
- Generated 47.8% growth in CGuardâ„¢ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuardâ„¢ EPS, including a...
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR),...
Credited with performing the first ever endovascular repair procedure in 1990...
Successful live case transmission again demonstrated CGuard’s™ differentiated patient protection features and ease of use...
Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuardâ„¢ Embolic Prevention System (EPS) ...
      - 20% growth in CGuard™ revenue Year-over-Year -            - C-Guardian FDA IDE Trial Completes First European Enrollment -            - Held...
Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET...
Tuesday, March 22nd @ 2 p.m. ET...
- CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- - Published CGuard Clinical trial results in Journals of the...